Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial.
Del Prato S, Blonde L, Martinez L, Göke B, Woo V, Millward A, Gomis R, Canovatchel B, Strack T, Lawrence D, Freemantle N; EXPERIENCE Trial Team. Del Prato S, et al. Diabet Med. 2008 Jun;25(6):662-70. doi: 10.1111/j.1464-5491.2008.02438.x. Epub 2008 Apr 23. Diabet Med. 2008. PMID: 18435781 Clinical Trial.
In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A. Bruttomesso D, et al. Among authors: del prato s. Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x. Diabet Med. 2008. PMID: 18307459 Clinical Trial.
Three-year efficacy of complex insulin regimens in type 2 diabetes.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group. Holman RR, et al. N Engl J Med. 2009 Oct 29;361(18):1736-47. doi: 10.1056/NEJMoa0905479. Epub 2009 Oct 22. N Engl J Med. 2009. PMID: 19850703 Free article. Clinical Trial.
Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes.
Matthews DR, Paldánius PM, Proot P, Foley JE, Stumvoll M, Del Prato S. Matthews DR, et al. Among authors: del prato s. Diabet Med. 2019 Apr;36(4):505-513. doi: 10.1111/dme.13886. Epub 2019 Feb 12. Diabet Med. 2019. PMID: 30576013 Free PMC article. Clinical Trial.
Response letter to D. Singh-franco et al.
Owens DR, Del Prato S, Taskinen MR, Gomis R, Forst T, Woerle HJ. Owens DR, et al. Among authors: del prato s. Diabetes Obes Metab. 2012 Nov;14(11):1054-5. doi: 10.1111/j.1463-1326.2012.01623.x. Diabetes Obes Metab. 2012. PMID: 23034010 No abstract available.
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Del Prato S, Foley JE, Kothny W, Kozlovski P, Stumvoll M, Paldánius PM, Matthews DR. Del Prato S, et al. Diabet Med. 2014 Oct;31(10):1178-84. doi: 10.1111/dme.12508. Epub 2014 Jul 17. Diabet Med. 2014. PMID: 24863949 Free PMC article. Clinical Trial.
Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe.
Hambling CE, Khunti K, Cos X, Wens J, Martinez L, Topsever P, Del Prato S, Sinclair A, Schernthaner G, Rutten G, Seidu S. Hambling CE, et al. Among authors: del prato s. Prim Care Diabetes. 2019 Aug;13(4):330-352. doi: 10.1016/j.pcd.2018.12.005. Epub 2019 Feb 18. Prim Care Diabetes. 2019. PMID: 30792156 Review.
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
Gomis R, Owens DR, Taskinen MR, Del Prato S, Patel S, Pivovarova A, Schlosser A, Woerle HJ. Gomis R, et al. Among authors: del prato s. Int J Clin Pract. 2012 Aug;66(8):731-740. doi: 10.1111/j.1742-1241.2012.02975.x. Epub 2012 Jun 12. Int J Clin Pract. 2012. PMID: 22691164
New-onset diabetes after kidney transplantation.
Giannarelli R, Coppelli A, Boggi U, Rizzo G, Barsotti M, Palaeologo G, Tregnaghi C, Mosca F, Del Prato S, Marchetti P. Giannarelli R, et al. Among authors: del prato s. Diabet Med. 2005 Aug;22(8):1125-6. doi: 10.1111/j.1464-5491.2005.01621.x. Diabet Med. 2005. PMID: 16026388 No abstract available.
546 results